文献速递消化道肿瘤放疗姑息放疗与转移瘤放疗物理与技术

MRI引导立体定向放疗治疗肝转移瘤:MOMENTUM研究耐受性、急性毒性与生活质量结果

Liver Metastases Treated With Magnetic Resonance Imaging Guided Stereotactic Body Radiation Therapy: Outcomes of Tolerability, Acute Toxicity, and Quality of Life From the MOMENTUM Study.
PubMed 文献 · Pract Radiat Oncol · 2025-08-21

MOMENTUM前瞻性多中心登记研究纳入135例肝转移瘤患者,接受1.5T MR-Linac引导SBRT,97%完成治疗且无因耐受性差中断,仅1例(0.9%)急性3级放疗相关毒性(胃炎),无≥4级毒性。3个月时QLQ-C30和EQ-5D-5L在角色功能、恶心、疲乏、便秘、疼痛5个领域出现5-10分具临床意义的恶化,与CT引导SBRT相当。

要点

  • MRI引导肝SBRT耐受性好,97%完成治疗且无因耐受性中断。
  • 急性3级放疗相关毒性仅1例(0.9%,胃炎),无≥4级毒性。
  • 3个月生活质量5个领域恶化5-10分,与CT引导SBRT相当。

核心结论

  • MRI引导SBRT对肝转移瘤患者耐受性好且安全,97%治疗成功完成,仅1例急性3级放疗相关毒性,无≥4级毒性。
  • 生活质量在5个领域出现≥5分的临床相关恶化,与CT引导SBRT相当。

研究设计与样本

  • 前瞻性多中心登记研究(MOMENTUM,NCT04075305),纳入2019年4月至2023年4月在1.5T MR-Linac上治疗的肝转移瘤患者。
  • 共135例患者,中位年龄67岁(范围31-93),来自4个国家7家机构。
  • 采用描述性统计报告治疗耐受性、急性毒性(CTCAE v5.0)及基线至治疗后3个月生活质量问卷(QLQ-C30和EQ-5D-5L)。

主要发现

  • 原发肿瘤最常见为结直肠癌(50%)和肺癌(12%)。
  • 处方SBRT总剂量20.0-67.5 Gy,分2-12次,每次7-22.5 Gy(中位生物有效剂量180 Gy,范围59.5-540 Gy)。
  • 97%(131例)患者完成治疗,无因耐受性差中断。
  • 至3个月,12例(10.6%)报告14项3级毒性,仅1项(0.9%)为放疗相关(胃炎),无≥4级毒性。

关键数值与推荐

  • 急性毒性按NCI CTCAE v5.0分级,生活质量用QLQ-C30和EQ-5D-5L评估。
  • 临床相关恶化定义为≥5分。

临床怎么用

  • MRI引导SBRT可作为肝转移瘤的耐受性良好且安全的局部治疗选择。
  • 治疗前应告知患者3个月时角色功能、恶心、疲乏、便秘和疼痛可能出现轻度至中度恶化。

局限性

  • 仅报告至3个月的急性毒性和生活质量结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) is a local treatment option for liver metastases. The introduction of magnetic resonance imaging (MRI) guided SBRT has paved the way for optimal treatment outcomes by improving tumor visualization, daily plan adaptation and margin reduction. The purpose of this study was to review the tolerability of MRI-guided liver SBRT and to present early toxicity and quality of life (QoL) outcomes from a prospective multicenter registry. METHODS AND MATERIALS: All patients enrolled in the MOMENTUM study (NCT04075305) who were treated for liver metastases between April 2019 and April 2023 on a 1.5T MR-Linac were included. Descriptive statistics were used to present tolerability of treatment, acute toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0) and Quality of Life questionnaires (QLQ-C30 and EQ-5D-5L) at baseline and 3 months after treatment. RESULTS: A total of 135 patients (median age, 67 years; range, 31-93) were treated in 7 institutes across 4 countries. The most common primary tumor origins were colorectal (50%) and lung cancer (12%). Prescribed total SBRT doses ranged from 20.0 to 67.5 Gy, delivered in 2 to 12 fractions of 7 to 22.5 Gy per fraction (median biologically effective dose, 180 Gy; range, 59.5-540 Gy). A total of 97% of patients (n = 131) completed their treatment, with no interruptions due to poor tolerability. Up to 3 months, 14 grade 3 toxicities were reported in 12 patients (10.6%), with only 1 (0.9%) recorded as radiation therapy related (gastritis). No grade ≥4 toxicities were reported. Sixty-two and 63 patients completed the QLQ-C30 and EQ-5D-5L questionnaires at both time points, respectively. These showed a worsening of 5 to 10 points at 3 months for role functioning, nausea, fatigue, constipation, and pain. CONCLUSIONS: In this prospective cohort, 97% of treatments were well tolerated and completed successfully, with only 1 case of acute grade 3 radiation therapy related toxicity and no grade ≥4 toxicity reported. QoL outcomes showed clinically relevant worsening (defined as ≥5 points) in 5 domains, which is comparable to that of computed tomography (CT-) guided SBRT. Overall, the outcomes showed that MRI-guided SBRT is a well-tolerated and safe treatment for patients with liver metastases.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Peltenburg JE, Westley R, Daamen LA, et al. Liver Metastases Treated With Magnetic Resonance Imaging Guided Stereotactic Body Radiation Therapy: Outcomes of Tolerability, Acute Toxicity, and Quality of Life From the MOMENTUM Study. Pract Radiat Oncol. 2025. PMID: 40849040. doi:10.1016/j.prro.2025.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。